Alnylam Pharmaceuticals | ALNY - Net Income


Alnylam Pharmaceuticals reported $186.42M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 113M Sep/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Takeda JPY 103.64B 115.44B Dec/2025
Tectonic Therapeutic USD -19.04M 940K Sep/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xencor USD -6.03M 24.8M Sep/2025